Biocon Gains Health Canada Nod for Denosumab Biosimilars
Toronto, Canada & Bengaluru, India, April 21, 2026 In a significant advancement for global biosimilars and bone health therapeutics,...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Toronto, Canada & Bengaluru, India, April 21, 2026 In a significant advancement for global biosimilars and bone health therapeutics,...
BENGALURU, India & BRIDGEWATER, New Jersey, United States, April 7, 2026 Biocon Limited announced the U.S. commercial launch of...
CRANBURY, New Jersey, September 11, 2025 — Biocon Limited has inaugurated its first U.S. manufacturing facility in Cranbury, New...
